Sumin Thapa

Dr. Sumin Thapa

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RDRavneet Kaur Dhanoa
Ravneet Kaur Dhanoa
Sumin ThapaSumin Thapa
Sumin Thapa
PKPragnan Kancharla
Pragnan Kancharla
SKShweta Kurian
Shweta Kurian
Background/Objectives: CDK4/6i and ET improve outcomes in HR-positive, HER2-negative breast cancer, but their benefits differ between early-stage (EBC) and metastatic disease (MBC). We aimed to compare the efficacy and toxicity of CDK4/6i plus ET versus ET alone across these disease settings. Methods: We conducted a meta-analysis of phase III randomized trials identified through MEDLINE, EMBASE, and Web of Science up to 1 October 2025. Twenty-two trials (18 MBC, n = 6364; 4 EBC, n = 17,741) met the inclusion criteria. Two reviewers extracted data and assessed risk of bias. The study followed PRISMA 2020 guidelines (PROSPERO: CRD420251132302). Outcomes included overall survival (OS), progression-free survival (PFS), invasive disease-free survival (iDFS), distant relapse-free survival (DRFS), response rates, treatment discontinuation (TDR), dose reductions (DRR), and grade 3–4 adverse events. Results: In MBC, CDK4/6i improved OS (HR: 0.78, 95% CI: 0.72–0.85) and PFS (HR: 0.53, 95% CI: 0.50–0.56) and increased objective response, clinical benefit, and disease control rates along with TDR, DRR, and grade 3–4 adverse events. In EBC, iDFS improved, whereas OS (HR: 0.92, 95% CI: 0.75–1.12; p = 0.40) and DRFS did not. TDR, DRR, and grade 3–4 adverse events were increased. Conclusions: CDK4/6i confer significant OS and PFS benefits in MBC, supporting first-line use. In EBC, no OS benefit was observed, and toxicity was increased, underscoring the need for individualized risk–benefit assessment. Longer follow-up is warranted to clarify survival outcomes.


10 October 2026 in The American Journal of Patient Health Info
Verified
Journal Article
Open access
Sumin ThapaSumin Thapa
Sumin Thapa
Adverse pregnancy outcomes, including preeclampsia, gestational diabetes, early birth, a smaller than expected baby, and pregnancy loss, can give early clues about a woman's future heart health. Women who have had them are more likely to develop heart disease, stroke, and heart failure, with preeclampsia raising the risk of heart failure about four times and gestational diabetes raising the risk of type 2 diabetes about 10 times. Regular checks of blood pressure, blood sugar, cholesterol, and weight can find problems early and should continue for life. Exercise, a Mediterranean diet, a healthy weight, and not smoking can lower heart risk, and some women also need medicine. Women should see a doctor before another pregnancy, and those at high risk of preeclampsia may be advised to take low-dose aspirin after 12 weeks. Severe headache, blurred vision, or trouble breathing at rest during pregnancy need urgent care. A difficult pregnancy does not make heart disease certain, but it is an early warning while there is still time to act.

5 May 2026 in Nepal Journal of Dermatology, Venereology & Leprology
Verified
Journal Article
Open access
SSSubash Swar
Subash Swar
AYAbhiraj Yadav
Abhiraj Yadav
STSumin Thapa
Sumin Thapa
Sumin ThapaSumin Thapa
Sumin Thapa
Impetigo is a common, contagious superficial bacterial skin infection predominantly affecting children aged two to five years. Severe presentations are rare but can be diagnostically and therapeutically challenging, particularly in rural, resource-limited settings. We report a 7-year-old girl from rural Nepal with severe non-bullous impetigo contagiosa unresponsive to initial therapy with topical mupirocin and oral cephalexin. Due to the absence of culture and sensitivity facilities and the high regional prevalence of methicillin-resistant Staphylococcus aureus (MRSA), empirical oral doxycycline was initiated. Marked improvement occurred within 48 hours, with complete resolution by day 7. This case underscores the importance of flexible, evidence-based empirical therapy for suspected MRSA in pediatric patients when diagnostic resources are unavailable, and highlights the short-term safety and efficacy of doxycycline in children.